Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 43 71
Mouth Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 43 D009059
NCIt 49 C27641 C3240
UMLS 71 C0026636

Summaries for Mouth Disease

MedlinePlus : 42 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and stomatitis, and has symptoms including tinnitus, halitosis and snoring. An important gene associated with Mouth Disease is G3BP1 (G3BP Stress Granule Assembly Factor 1), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include mouth, testes and kidney, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 502, show less)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 35.1 TLR7 TLR4 TLR3 SCARB2 IL6 IL13
2 stomatitis 32.1 TLR4 IL6 IL10 IFNG DDX58
3 exanthem 32.0 IL6 IL10 CRP
4 encephalitis 31.9 TLR3 IRF3 IL6 IL10 DDX58
5 herpangina 31.9 TP53 TLR7 TLR4 TLR3 IL6 IL10
6 myocarditis 31.9 TLR4 TLR3 IL6 IL10 IFNG
7 poliomyelitis 31.7 SCARB2 IL10 IFNG
8 pulmonary edema 31.6 IL13 IL10 CRP
9 dermatitis 31.4 TLR4 IL6 IL13 IL10 IFNG
10 viral infectious disease 31.4 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
11 rhinitis 31.4 IL6 IL13 IL10 IFNG
12 vaccinia 31.4 TP53 STAT1 IRF3 IL6
13 brucellosis 31.4 TLR4 IL6 IL10 IFNG CRP
14 chickenpox 31.4 TLR3 STAT1 IL6 IL10 IFNG CRP
15 plague 31.3 TLR4 IL6 IL10 DDX58
16 meningitis 31.3 TLR4 IL6 IL10 IFNG CRP
17 allergic hypersensitivity disease 31.2 TLR4 IL13 IL10 IFNG
18 measles 31.2 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
19 viral encephalitis 31.2 TLR3 IL6 IL10
20 meningoencephalitis 31.2 IL6 IL10 CRP
21 aphthous stomatitis 31.2 TLR4 IL6 IL10 IFNG
22 hepatitis a 31.1 TLR4 TLR3 IL10 IFNG
23 diarrhea 31.1 TLR4 IL6 IL10 IFNG
24 skin disease 31.0 VTN VDR TLR4 IL6 IL13 IL10
25 trypanosomiasis 31.0 TLR4 STAT1 IL6 IL10 IFNG
26 rabies 31.0 TLR3 STAT1 IRF3 DDX58
27 dermatitis, atopic 31.0 TLR7 TLR4 TLR3 STAT1 IL6 IL17F
28 chorioretinitis 30.9 IL6 IL10 IFNG
29 chlamydia 30.9 TLR4 IL6 IL10 IFNG CRP
30 endocarditis 30.9 IL6 IL10 IFNG CRP
31 acute pancreatitis 30.9 TLR4 IL6 IL10 CRP
32 tetanus 30.9 IL6 IL13 IL10 IFNG CRP
33 human immunodeficiency virus type 1 30.9 TLR3 STAT1 IRF3 IL6 IL10 IFNG
34 severe acute respiratory syndrome 30.8 STAT1 IRF3 IL6 IL10 IFNG DDX58
35 influenza 30.8 TLR7 TLR3 STAT1 IRF3 IL6 IFNG
36 immune deficiency disease 30.8 VDR STAT1 IL6 IL13 IL10 IFNG
37 herpes simplex 30.8 TLR3 STAT1 IRF3 DDX58
38 bronchopneumonia 30.7 TLR4 IL6 IL10 CRP
39 encephalomalacia 30.7 TLR4 IL6 CRP
40 neuroretinitis 30.7 IFNG CRP
41 appendicitis 30.7 TLR4 IL6 IL10 IFNG CRP
42 acute myocarditis 30.7 TLR3 STAT1 IL6 IL10 CRP
43 tonsillitis 30.7 TLR4 TLR3 IL6 IL10 IFNG
44 common cold 30.7 TLR4 TLR3 IL6 IL13 IL10
45 pericarditis 30.7 VTN IL6 IFNG CRP
46 peritonitis 30.7 TLR4 IL6 IL10 IFNG CRP
47 gastroenteritis 30.7 IL6 IL10 IFNG CRP
48 acquired immunodeficiency syndrome 30.7 TP53 IL6 IL10 IFNG CRP
49 conjunctivitis 30.7 TLR3 IL6 IL13 IL10 IFNG
50 perinatal necrotizing enterocolitis 30.7 TLR7 TLR4 TLR3 IL6 IL10 CRP
51 tick-borne encephalitis 30.7 TLR3 IL10 DDX58
52 posterior uveitis 30.7 IL6 IL13 IFNG
53 viral hepatitis 30.7 TLR4 TLR3 IL6 IL10 IFNG CRP
54 periodontitis 30.7 VDR TLR4 IL6 IL10 IFNG CRP
55 bronchitis 30.6 TLR4 STAT1 IL6 IL13 IL10 CRP
56 hepatitis e 30.6 TLR3 IFNG DDX58
57 cellulitis 30.6 IL6 IL10 CRP
58 acute transverse myelitis 30.6 IL6 IL10
59 kaposi sarcoma 30.6 TP53 TLR3 STAT1 IRF3 IL6
60 fasciitis 30.6 TP53 IL6 IFNG
61 bone inflammation disease 30.6 TLR7 TLR4 TLR3 IL6 IL10 IFNG
62 cardiogenic shock 30.6 IL6 CRP
63 graft-versus-host disease 30.6 IL6 IL10 IFNG
64 herpes zoster 30.6 IL10 IFNG CRP
65 keratoconjunctivitis 30.6 IL6 IL13 IFNG
66 hydrocephalus 30.6 VTN TP53 TLR4 NOTCH1 IL10 IFNG
67 autoimmune disease 30.6 VDR IL6 IL17F IL13 IL10 IFNG
68 severe combined immunodeficiency 30.6 NOTCH1 IL6 IL13 IL10 IFNG
69 bronchiolitis 30.6 TLR7 TLR4 TLR3 IL6 IL13 IL10
70 purpura 30.6 IL6 IL10 CRP
71 psoriasis 30.5 VDR IL6 IL17F IL13 IL10 IFNG
72 glioblastoma multiforme 30.5 TP53 STAT1 NOTCH1 IL6 IL13 IFNG
73 brain edema 30.3 IL6 IFNG CRP
74 respiratory failure 30.2 IL6 IL13 IL10 CRP
75 burning mouth syndrome 11.6
76 prosthetic joint infection 10.9 TLR4 IL6 CRP
77 chlamydia pneumonia 10.9 TLR4 IL6 IL10 CRP
78 allergic contact dermatitis 10.8 IL6 IL10 IFNG
79 fallopian tube disease 10.8 TP53 TLR4 IL6 CRP
80 bolivian hemorrhagic fever 10.8 STAT1 IRF3 DDX58
81 eales disease 10.8 IL6 IL10 IFNG
82 gingival disease 10.8 TLR4 IL6 IL10 CRP
83 lung abscess 10.8 IL6 IFNG CRP
84 idiopathic neutropenia 10.8 TLR4 IL6 IL10
85 relapsing polychondritis 10.8 IL6 IL10 IFNG CRP
86 superficial basal cell carcinoma 10.8 TLR7 TLR4 TLR3
87 middle ear disease 10.8 TLR4 IL6 IL10 CRP
88 endometrial disease 10.8 TLR4 TLR3 IL6 IL10
89 epididymis disease 10.8 TLR4 IL6 CRP
90 dysentery 10.8 TLR4 IL6 IL10 CRP
91 anogenital venereal wart 10.8 TP53 TLR7 TLR4 TLR3
92 cystic echinococcosis 10.8 TLR4 IL6 IL10 IFNG
93 multicentric castleman disease 10.8 IL6 IL10 IFNG CRP
94 echinococcosis 10.8 TLR4 IL6 IL10 IFNG
95 castleman disease 10.8 IL6 IL10 IFNG CRP
96 primary peritoneal carcinoma 10.8 TP53 IL10 IFNG
97 viral pneumonia 10.8 TLR3 IL6 IL10 DDX58 CRP
98 mikulicz disease 10.8 IL13 IL10 CRP
99 orchitis 10.8 IL6 IL10 CRP
100 urethritis 10.8 TLR4 IL6 CRP
101 nickel allergic contact dermatitis 10.8 IL17F IL10 IFNG
102 cystitis 10.8 TP53 TLR4 IL6 CRP
103 combat disorder 10.8 TLR7 TLR4 TLR3
104 fungal meningitis 10.8 IL6 IL10 IFNG
105 african tick-bite fever 10.8 IL6 IL13 IL10 IFNG
106 funisitis 10.8 IL6 IL10 CRP
107 blood group, globoside system 10.8 TLR4 IL6 CRP
108 central nervous system vasculitis 10.8 IL6 IFNG CRP
109 scrub typhus 10.8 TLR4 IL10 IFNG CRP
110 acute cystitis 10.8 TLR4 IL6 IL10 CRP
111 paracoccidioidomycosis 10.8 TLR4 IL6 IL10 IFNG
112 leptospirosis 10.8 IL6 IL10 IFNG CRP
113 q fever 10.8 TLR4 IL6 IL10 IFNG
114 hyper ige recurrent infection syndrome 1 10.8 STAT1 IL6 IL17F IL10
115 subacute sclerosing panencephalitis 10.8 TLR3 IL6 IL10 IFNG
116 mucocutaneous leishmaniasis 10.8 TLR3 IL10 IFNG
117 cysticercosis 10.8 TLR4 IL6 IL10
118 septic arthritis 10.8 TLR4 TLR3 IFNG CRP
119 pyelitis 10.8 TLR4 IL6 CRP
120 listeriosis 10.8 TLR4 IRF3 IL6 IL10
121 primary systemic mycosis 10.8 TLR4 IL6 IL10 IFNG CRP
122 penile disease 10.8 TP53 TLR7 TLR4 TLR3 IL6
123 chronic conjunctivitis 10.8 IL6 IL13 IL10
124 chikungunya 10.8 TLR7 STAT1 IL6 G3BP2 G3BP1 DDX58
125 pleural disease 10.8 TP53 IL6 IFNG CRP
126 autoimmune disease of gastrointestinal tract 10.8 TLR4 IL6 IL10 IFNG
127 melioidosis 10.8 TLR4 IL6 IL10 IFNG
128 keratitis, hereditary 10.8 TLR4 TLR3 IL6 IL10
129 campylobacteriosis 10.8 VDR TLR4 STAT1 IFNG
130 spondylitis 10.8 IL6 IL10 IFNG CRP
131 chorioamnionitis 10.8 TLR4 IL6 IL10 CRP
132 typhoid fever 10.8 TLR4 IL6 IFNG CRP
133 macs syndrome 10.8 STAT1 IL10 IFNG
134 lymph node disease 10.8 TLR4 IL6 IL10 IFNG CRP
135 vaginitis 10.8 TLR4 IL6 IL10
136 contact dermatitis 10.8 TLR4 IL6 IL10 IFNG
137 hypersensitivity reaction type iv disease 10.8 TLR4 IL6 IL10 IFNG CRP
138 respiratory allergy 10.8 TLR4 IL6 IL13 IL10
139 lichen disease 10.8 TP53 IL6 IFNG
140 aggressive periodontitis 10.8 VDR TLR4 IL6 IL10
141 autoimmune gastritis 10.8 IL6 IL10 IFNG
142 familial mediterranean fever 10.8 TLR4 IL6 IL10 CRP
143 testicular disease 10.8 TP53 TLR4 IL6 IL10 IFNG
144 pyelonephritis 10.8 TLR4 IL6 IL10 IFNG CRP
145 extrapulmonary tuberculosis 10.8 VDR IL10 IFNG CRP
146 uveal disease 10.8 IL6 IL10 IFNG CRP
147 filariasis 10.8 TLR4 IL6 IL10 IFNG CRP
148 colitis 10.8 TLR4 IL6 IL13 IL10 IFNG
149 ileus 10.8 IL6 IL10 IFNG CRP
150 prostatitis 10.8 VDR TP53 IL6 IL10
151 autoimmune disease of endocrine system 10.8 IL6 IL17F IL10 IFNG
152 filarial elephantiasis 10.8 TLR4 IL13 IL10
153 autoimmune disease of eyes, ear, nose and throat 10.8 IL6 IL17F IL10
154 bacterial meningitis 10.8 TLR4 IL6 IL10 IFNG CRP
155 paranasal sinus disease 10.8 IL13 IL10 IFNG CRP
156 cholangitis 10.8 TP53 TLR4 IL6 IL10 CRP
157 alcoholic hepatitis 10.8 TLR4 IL6 IL10 CRP
158 panuveitis 10.8 IL6 IL10 CRP
159 bacterial pneumonia 10.8 TLR4 TLR3 IL6 IL10 CRP
160 ascaris lumbricoides infection 10.8 IL6 IL13 IFNG
161 lymphatic system disease 10.8 TP53 IL6 IL10 IFNG CRP
162 intermediate uveitis 10.8 IL6 IL10 IFNG
163 reactive arthritis 10.8 TLR4 IL6 IL10 IFNG CRP
164 penicillin allergy 10.8 IL13 IL10 IFNG
165 mycoplasma pneumoniae pneumonia 10.8 IL6 IL13 IL10 IFNG CRP
166 collagen disease 10.8 IL6 IL13 IL10 CRP
167 esophagitis 10.8 TP53 IL6 IL13 IL10
168 lichen planus 10.8 TP53 IL6 IL10 IFNG
169 acute pyelonephritis 10.8 IL6 IL10 CRP
170 pelvic inflammatory disease 10.8 TLR4 IL13 IFNG CRP
171 bacteriuria 10.8 TLR4 IL6 CRP
172 allergic conjunctivitis 10.8 TLR3 IL13 IL10 IFNG
173 toxic shock syndrome 10.8 TLR4 IL6 IL10 IFNG CRP
174 nasal cavity disease 10.8 TLR4 IL6 IL13 IL10 IFNG
175 lactose intolerance 10.8 VDR IL10 CRP
176 sebaceous gland disease 10.8 TLR4 IL6 CRP
177 adult-onset still's disease 10.8 TLR7 IL6 CRP
178 hair disease 10.8 VDR TP53 IL6 IL10
179 oral hairy leukoplakia 10.8
180 parasitic helminthiasis infectious disease 10.8 TLR4 IL6 IL13 IL10 IFNG
181 plasmodium falciparum malaria 10.8 IL6 IL10 IFNG CRP
182 radiculopathy 10.8 IL6 IL13 IL10
183 multidrug-resistant tuberculosis 10.8 VDR IL10 IFNG
184 cutaneous leishmaniasis 10.8 TLR4 IL6 IL13 IL10 IFNG
185 viral meningitis 10.8 IL6 IFNG CRP
186 microphthalmia with limb anomalies 10.8 TLR7 TLR3 STAT1 IRF3 DDX58
187 osteomyelitis 10.8 TLR4 STAT1 IL6 IL10 IFNG
188 colorectal adenoma 10.8 VDR TP53 IL6 CRP
189 aspergillosis 10.8 TLR4 TLR3 IL6 IL10 IFNG
190 relapsing-remitting multiple sclerosis 10.8 TLR7 TLR4 IL6 IL10 IFNG
191 mumps 10.8 TLR3 STAT1 IL6 IL10 IFNG
192 breast implant-associated anaplastic large cell lymphoma 10.8 TP53 IL13
193 toxoplasmosis 10.8 TLR4 STAT1 IL6 IL10 IFNG
194 juvenile rheumatoid arthritis 10.8 IL6 IL10 IFNG CRP
195 visceral leishmaniasis 10.8 TLR4 IL13 IL10 IFNG CRP
196 chronic fatigue syndrome 10.8 TLR4 IL6 IL13 IL10 IFNG
197 lymphadenitis 10.8 VDR TLR4 IL10 IFNG CRP
198 hellp syndrome 10.8 TLR4 IL6 IL10 CRP
199 streptococcus pneumonia 10.8 TLR7 TLR4 TLR3 IL6 IL10 CRP
200 rubella 10.8 TLR4 TLR3 IL6 IL10 IFNG DDX58
201 bacterial infectious disease 10.8 TLR4 TLR3 IL6 IL10 IFNG CRP
202 cryptococcosis 10.8 IL13 IL10 IFNG
203 rosacea 10.8 VDR IL6 CRP
204 spondyloarthropathy 10.8 IL6 IL17F IL10 IFNG
205 bacterial sepsis 10.8 TLR7 TLR4 TLR3 IL6 IL10 CRP
206 gastritis 10.8 TP53 TLR4 IL6 IL10
207 extrinsic cardiomyopathy 10.8 TLR7 TLR4 TLR3 IL6 IL10 CRP
208 nail disease 10.8 STAT1 IL6 IL17F
209 food allergy 10.8 TLR4 IL13 IL10 IFNG
210 schistosomiasis 10.8 TP53 IL13 IL10 IFNG
211 chagas disease 10.8 TLR4 IL6 IL10 IFNG
212 peanut allergy 10.8 IL13 IL10 IFNG
213 lymphocytic choriomeningitis 10.8 IRF3 IL6 DDX58
214 otitis media 10.8 TLR7 TLR4 IL6 IL10 IFNG CRP
215 conjunctival disease 10.8 TLR4 TLR3 IL6 IL13 IL10 CRP
216 crohn's disease 10.8 TLR4 IL6 IL10 IFNG CRP
217 splenic disease 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
218 ige responsiveness, atopic 10.8 IL13 IL10 IFNG
219 cold agglutinin disease 10.8 IL6 CRP
220 peripheral nervous system disease 10.8 TLR4 IL6 IL10 IFNG CRP
221 leukocyte disease 10.8 TP53 NOTCH1 IL6 IL13 IL10
222 hashimoto thyroiditis 10.8 VDR IL6 IL10 IFNG CRP
223 newcastle disease 10.8 TLR3 IRF3 DDX58
224 aicardi-goutieres syndrome 10.8 TLR7 TLR3 IRF3 DDX58
225 bronchiolitis obliterans 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
226 intervertebral disc disease 10.8 VDR IL6 IFNG
227 arteriosclerosis 10.8 TLR4 IL6 IL10 IFNG CRP
228 alopecia areata 10.8 VDR IL6 IL13 IL10 IFNG
229 proteasome-associated autoinflammatory syndrome 1 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
230 overnutrition 10.8 TLR4 IL6 IL10 CRP
231 plasmodium vivax malaria 10.8 IL6 IL10 IFNG
232 pulmonary tuberculosis 10.8 VDR TLR4 IL6 IL10 IFNG CRP
233 preterm premature rupture of the membranes 10.8 TLR4 IL6 CRP
234 invasive aspergillosis 10.8 TLR4 IL10 IFNG
235 splenic diffuse red pulp small b-cell lymphoma 10.8 TP53 NOTCH1
236 cutaneous lupus erythematosus 10.8 IL6 IL10 IFNG
237 rheumatic fever 10.8 IL6 IL10 IFNG
238 west nile virus 10.8 TLR3 IRF3 DDX58
239 intermittent claudication 10.8 IL6 IL10 CRP
240 pleurisy 10.8 TLR4 IFNG CRP
241 psoriatic arthritis 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
242 arthritis 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
243 bone cancer 10.8 VDR TP53 NOTCH1 IL6
244 cryoglobulinemia 10.8 IL6 IL10 IFNG
245 pancytopenia 10.8 TP53 IL6 IFNG CRP
246 vaginal disease 10.8 TP53 TLR7 TLR4 TLR3 IL6 IL10
247 allergic asthma 10.8 TLR4 IL13 IL10 IFNG
248 anus disease 10.8 TP53 TLR7 TLR4 TLR3 IL6 IL10
249 basal cell carcinoma 10.8 VDR TP53 NOTCH1 IL6 IL10
250 lepromatous leprosy 10.8 VDR IL10 IFNG
251 rectal disease 10.8 TP53 TLR7 TLR4 TLR3 IL6 IL10
252 ulcerative colitis 10.8 TLR4 IL6 IL13 IL10 IFNG CRP
253 ileitis 10.8 TLR4 IL6 IL10
254 cinca syndrome 10.8 TLR4 IL6 CRP
255 glucose metabolism disease 10.8 TLR4 IL6 IL10 CRP
256 pulmonary disease, chronic obstructive 10.8 TLR4 IL6 IL13 IL10 CRP
257 central nervous system lymphoma 10.8 TP53 IL6 IL10
258 chronic mucocutaneous candidiasis 10.8 TLR3 STAT1 IL6 IL17F IL10 IFNG
259 hepatitis b 10.8 TP53 TLR4 TLR3 STAT1 IL6 IFNG
260 mixed connective tissue disease 10.8 IL6 IL10 IFNG
261 coccidiosis 10.8 TLR7 TLR4 TLR3 IL6 IL10 IFNG
262 interstitial lung disease 10.8 VTN IL6 IL13 IL10 IFNG CRP
263 commensal bacterial infectious disease 10.8 TLR7 TLR4 TLR3 IL6 IL10 IFNG
264 sarcoidosis 1 10.8 STAT1 IL13 IFNG CRP
265 spotted fever rickettsiosis 10.8 IL10 IFNG
266 autoimmune disease of musculoskeletal system 10.8 TLR7 TLR4 TLR3 IL6 IL10 IFNG
267 mycobacterium tuberculosis 1 10.8 VDR TLR4 STAT1 IL10 IFNG CRP
268 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL6 IL13
269 human immunodeficiency virus infectious disease 10.8 TLR7 STAT1 IL10 IFNG
270 hepatitis c 10.8 TLR3 STAT1 IRF3 IL10 IFNG DDX58
271 bacterial vaginosis 10.8 TLR4 IL6 IL10
272 cryopyrin-associated periodic syndrome 10.8 IL6 CRP
273 lung disease 10.8 TP53 TLR4 IL6 IL13 IL10 IFNG
274 leprosy 3 10.8 VDR TLR7 TLR4 TLR3 IL6 IL10
275 muscular disease 10.8 TP53 TLR4 NOTCH1 IL6 IL10 CRP
276 rheumatic disease 10.8 VTN IL10 IFNG CRP
277 obstructive jaundice 10.8 TLR4 IL6 CRP
278 leishmaniasis 10.8 TLR4 STAT1 IL6 IL13 IL10 IFNG
279 coronary stenosis 10.8 TLR4 IL6 CRP
280 dengue hemorrhagic fever 10.8 TLR7 TLR3 STAT1 IL6 IL13 IL10
281 acquired metabolic disease 10.8 TLR4 IL6 IL10 CRP
282 primary biliary cirrhosis 10.8 VDR TLR4 TLR3 IL6 IL10 IFNG
283 candidiasis 10.8 TLR4 TLR3 STAT1 IL6 IL17F IL10
284 tropical spastic paraparesis 10.8 IL6 IL10 IFNG
285 diabetes mellitus 10.8 VTN VDR TLR4 IL6 IL10 IFNG
286 aplastic anemia 10.7 VDR TP53 NOTCH1 IL6 IL10 IFNG
287 rheumatoid arthritis 10.7 TLR4 IL6 IL13 IL10 IFNG CRP
288 thrombocytopenia 10.7 TLR7 TLR4 STAT1 IL6 IL10 IFNG
289 uremic pruritus 10.7 IL6 CRP
290 upper respiratory tract disease 10.7 TP53 TLR4 TLR3 IL6 IL13 IL10
291 connective tissue disease 10.7 TLR4 IL6 IL10 IFNG CRP
292 nose disease 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
293 systemic autoimmune disease 10.7 IL6 CRP
294 yellow fever 10.7 STAT1 IL6 CRP
295 parasitic protozoa infectious disease 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
296 bronchial disease 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
297 primary bacterial infectious disease 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
298 temporal arteritis 10.7 IL6 IFNG CRP
299 pulmonary fibrosis, idiopathic 10.7 TP53 TLR4 TLR3 IL6 IL13 IL10
300 immune system disease 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
301 celiac disease 1 10.7 TLR7 TLR4 TLR3 IL6 IL13 IL10
302 pre-malignant neoplasm 10.7 TP53 TLR7 NOTCH1
303 b-cell growth factor 10.7 IL6 IFNG
304 salmonellosis 10.7 VDR TLR7 TLR4 TLR3 STAT1 IL6
305 duodenal ulcer 10.7 TLR4 IL6 IL10
306 pneumonia 10.7 VTN TLR7 TLR4 IL6 IL13 IL10
307 autoimmune disease of central nervous system 10.7 TLR7 TLR4 TLR3 IL6 IL17F IL13
308 niemann-pick disease 10.7 TLR4 IL6 IL10
309 eye disease 10.7 VDR TP53 TLR4 IL6 IL13 IL10
310 vascular disease 10.7 VTN TP53 TLR4 STAT1 IL6 IL10
311 skin squamous cell carcinoma 10.7 TP53 STAT1 IL10
312 gingivitis 10.7 IL6 IL10 IFNG
313 alcoholic liver cirrhosis 10.7 TLR4 IL6 IL10
314 neuritis 10.7 IL6 IL10 IFNG
315 cervical cancer 10.7 TP53 TLR4 STAT1 NOTCH1 IL6 IL10
316 leukemia, chronic lymphocytic 10.7 TP53 TLR7 STAT1 NOTCH1 IL6 IL10
317 osteoporosis 10.7 VDR TP53 TLR4 STAT1 IL6 IL10
318 myelodysplastic syndrome 10.7 TP53 STAT1 NOTCH1 IL6 IL10 IFNG
319 lyme disease 10.7 TLR7 IL6 CRP
320 chronic graft versus host disease 10.7 IL10 IFNG
321 body mass index quantitative trait locus 11 10.7 TP53 TLR4 TLR3 STAT1 IL6 IL10
322 takayasu arteritis 10.7 IL6 IL10 CRP
323 behcet syndrome 10.7 TLR7 TLR4 TLR3 IL6 IL17F IL13
324 maxillary sinus adenocarcinoma 10.7 TP53 STAT1
325 diabetes mellitus, insulin-dependent 10.7 VDR TLR7 TLR4 TLR3 IL6 IL13
326 macular degeneration, age-related, 1 10.7 VTN TLR4 TLR3 IL6 CRP
327 pericardial tuberculosis 10.7 IFNG CRP
328 atrophic gastritis 10.7 TP53 IL6 IL10
329 dilated cardiomyopathy 10.7 TP53 TLR4 TLR3 IL6 IL10 IFNG
330 skeletal tuberculosis 10.7 IFNG CRP
331 noonan syndrome 1 10.7 TLR4 STAT1 IRF3 EIF4G1 DDX58
332 hypertension, essential 10.7 VDR TP53 TLR7 TLR4 TLR3 IL6
333 bone resorption disease 10.7 VDR IL6 CRP
334 malaria 10.7 VDR TP53 TLR4 IL6 IL17F IL13
335 diabetes mellitus, noninsulin-dependent 10.7 VDR TP53 TLR7 TLR4 TLR3 STAT1
336 opportunistic mycosis 10.7 TLR7 TLR4 TLR3 STAT1 IL6 IL17F
337 sclerosing cholangitis 10.7 TLR4 IL6 IL10
338 myeloma, multiple 10.6 VTN TP53 TLR7 TLR4 TLR3 STAT1
339 multiple sclerosis 10.6 VTN VDR TLR4 TLR3 STAT1 IL6
340 non-alcoholic fatty liver disease 10.6 TLR4 IL6 IL10 CRP
341 inflammatory bowel disease 10.6 VDR TP53 TLR4 TLR3 STAT1 IL6
342 asthma 10.6 VTN VDR TLR4 TLR3 STAT1 IL6
343 irritable bowel syndrome 10.6 TLR4 IL6 IL10
344 disseminated intravascular coagulation 10.6 IL6 IL10 CRP
345 tuberculous peritonitis 10.6 IFNG CRP
346 systemic lupus erythematosus 10.6 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
347 tinea unguium 10.6 STAT1 CRP
348 bone remodeling disease 10.6 VDR IL6 CRP
349 pancreatic adenocarcinoma 10.6 TP53 STAT1 NOTCH1 IL6 IL10
350 fibromyalgia 10.5 IL6 IL10 CRP
351 corneal disease 10.5 TLR4 IL6 IL10
352 intracranial berry aneurysm 10.5 TLR4 IL6 CRP
353 aseptic meningitis 10.5
354 sleep apnea 10.4 IL6 IL10 CRP
355 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
356 colorectal cancer 10.4 VDR TP53 TLR7 TLR4 TLR3 STAT1
357 aortic disease 10.3 NOTCH1 IL6 CRP
358 cytokine deficiency 10.3
359 cholera 10.2
360 lymphopenia 10.2
361 mastitis 10.1
362 hyperglycemia 10.1
363 48,xyyy 10.1
364 myoclonus 10.1
365 hydrops, lactic acidosis, and sideroblastic anemia 10.1
366 erythema multiforme 10.1
367 47,xyy 10.1
368 helix syndrome 10.1
369 myelitis 10.0
370 ocular motor apraxia 10.0
371 rhabdomyosarcoma 10.0
372 avian influenza 10.0
373 guillain-barre syndrome 9.9
374 anthrax disease 9.9
375 nervous system disease 9.9
376 eczema herpeticum 9.9
377 tremor 9.9
378 ataxia and polyneuropathy, adult-onset 9.9
379 cyanosis, transient neonatal 9.9
380 nail disorder, nonsyndromic congenital, 10 9.9
381 japanese encephalitis 9.9
382 post-traumatic stress disorder 9.9
383 retinitis 9.9
384 syphilis 9.9
385 pancreatitis 9.9
386 acute stress disorder 9.9
387 vasculitis 9.9
388 venezuelan equine encephalitis 9.9
389 aceruloplasminemia 9.8
390 dengue virus 9.8
391 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
392 pasteurellosis 9.8
393 rift valley fever 9.8
394 coccidioidomycosis 9.8
395 cryptosporidiosis 9.8
396 hepatitis d 9.8
397 constipation 9.8
398 dental caries 9.8
399 central nervous system disease 9.8
400 embryoma 9.8
401 viral exanthem 9.8
402 scotoma 9.8
403 tracheitis 9.8
404 autoimmune gastrointestinal dysmotility 9.8
405 transverse myelitis 9.8
406 febrile seizures 9.8
407 meningitis and encephalitis 9.8
408 argyria 9.8
409 pernicious anemia 9.7
410 vitamin b12 deficiency 9.7
411 atrophic glossitis 9.7
412 glossitis 9.7
413 glossodynia 9.7
414 breast cancer 9.6
415 myositis 9.6
416 polykaryocytosis inducer 9.6
417 dowling-degos disease 1 9.6
418 testicular torsion 9.6
419 triiodothyronine receptor auxiliary protein 9.6
420 enterocolitis 9.6
421 hydrocephalus, congenital, 1 9.6
422 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 9.6
423 epilepsy, progressive myoclonic, 4, with or without renal failure 9.6
424 cd4/cd8 t-cell ratio 9.6
425 yemenite deaf-blind hypopigmentation syndrome 9.6
426 ventricular fibrillation, paroxysmal familial, 1 9.6
427 creatinine clearance quantitative trait locus 9.6
428 severe cutaneous adverse reaction 9.6
429 hepatitis c virus 9.6
430 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
431 kawasaki disease 9.6
432 vertigo, benign recurrent, 2 9.6
433 leukemia, acute lymphoblastic 3 9.6
434 pachyonychia congenita 3 9.6
435 frontometaphyseal dysplasia 2 9.6
436 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.6
437 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.6
438 rocky mountain spotted fever 9.6
439 swine influenza 9.6
440 metabolic acidosis 9.6
441 inguinal hernia 9.6
442 spotted fever 9.6
443 acute hemorrhagic conjunctivitis 9.6
444 autonomic nervous system disease 9.6
445 visual epilepsy 9.6
446 nephrotic syndrome 9.6
447 ecthyma 9.6
448 neutropenia 9.6
449 hypochondriasis 9.6
450 uveitis 9.6
451 facial paralysis 9.6
452 azoospermia 9.6
453 pleuropneumonia 9.6
454 dumping syndrome 9.6
455 status epilepticus 9.6
456 gaucher's disease 9.6
457 pharyngitis 9.6
458 larynx cancer 9.6
459 acrodermatitis 9.6
460 glucosephosphate dehydrogenase deficiency 9.6
461 mammary paget's disease 9.6
462 plasmacytoma 9.6
463 pustulosis of palm and sole 9.6
464 liver cirrhosis 9.6
465 scrapie 9.6
466 kidney disease 9.6
467 subacute thyroiditis 9.6
468 thyroiditis 9.6
469 impetigo 9.6
470 bullous pemphigoid 9.6
471 scarlet fever 9.6
472 pityriasis rosea 9.6
473 hard palate cancer 9.6
474 pemphigus 9.6
475 speech disorder 9.6
476 intracranial hypertension 9.6
477 babesiosis 9.6
478 ulcerative stomatitis 9.6
479 tenosynovitis 9.6
480 hypereosinophilic syndrome 9.6
481 hypoglycemia 9.6
482 bap1 tumor predisposition syndrome 9.6
483 acute flaccid myelitis 9.6
484 acute graft versus host disease 9.6
485 carcinoma showing thymus-like differentiation 9.6
486 central serous chorioretinopathy 9.6
487 familial episodic pain syndrome 9.6
488 gianotti crosti syndrome 9.6
489 granulocytopenia 9.6
490 granulosa cell tumor of the ovary 9.6
491 haemophilus influenzae 9.6
492 hemorrhagic shock and encephalopathy syndrome 9.6
493 leukoplakia 9.6
494 pityriasis lichenoides 9.6
495 pityriasis lichenoides et varioliformis acuta 9.6
496 st anthony's fire 9.6
497 seizure disorder 9.6
498 posttransplant acute limbic encephalitis 9.6
499 rapidly involuting congenital hemangioma 9.6
500 acute sensory ataxic neuropathy 9.6
501 erythema multiforme major 9.6
502 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.6

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


tinnitus, halitosis, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

26 (showing 10, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.44 CRP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.44 IL10
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.44 TLR4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.44 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.44 EIF4G1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.44 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.44 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 CRP EIF4G1 IL10 TLR4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.44 CRP
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.44 EIF4G1

MGI Mouse Phenotypes related to Mouth Disease:

45 (showing 19, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 DDX58 IFNG IL10 IL13 IL17F IL6
2 homeostasis/metabolism MP:0005376 10.41 CRP DDX58 IFNG IL10 IL13 IL6
3 immune system MP:0005387 10.4 CRP DDX58 IFNG IL10 IL13 IL17F
4 cellular MP:0005384 10.39 DDX58 G3BP1 IFNG IL10 IL13 IL6
5 cardiovascular system MP:0005385 10.36 CRP G3BP1 IFNG IL10 IL6 NOTCH1
6 growth/size/body region MP:0005378 10.36 DDX58 G3BP1 IFNG IL10 IL13 IL17F
7 mortality/aging MP:0010768 10.34 DDX58 G3BP1 G3BP2 IFNG IL10 IL13
8 digestive/alimentary MP:0005381 10.3 DDX58 IFNG IL10 IL13 IL17F IL6
9 integument MP:0010771 10.13 IFNG IL10 IL13 IL6 NOTCH1 STAT1
10 craniofacial MP:0005382 10.11 G3BP1 IFNG IL10 IL17F NOTCH1 TP53
11 muscle MP:0005369 10.1 IFNG IL10 IL13 IL6 NOTCH1 STAT1
12 nervous system MP:0003631 10.1 G3BP1 IFNG IL10 IL13 IL6 NOTCH1
13 liver/biliary system MP:0005370 10.06 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
14 neoplasm MP:0002006 10.02 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
15 hearing/vestibular/ear MP:0005377 10.01 IL13 NOTCH1 SCARB2 TLR4 TP53 VDR
16 normal MP:0002873 9.91 EIF4G1 IFNG IL10 IL17F NOTCH1 STAT1
17 renal/urinary system MP:0005367 9.76 IFNG IL6 NOTCH1 SCARB2 TLR4 TLR7
18 respiratory system MP:0005388 9.7 G3BP1 IFNG IL10 IL13 IL17F IL6
19 skeleton MP:0005390 9.36 IFNG IL10 IL13 IL17F IL6 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 95, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Antiviral Agents Phase 4
4 Antimetabolites Phase 4
5 Antibodies, Blocking Phase 4
6 Immunoglobulins Phase 4
7 Antibodies Phase 4
8 Vaccines Phase 4
9 Immunologic Factors Phase 4
10 Anti-Infective Agents Phase 3
11 Anti-Infective Agents, Local Phase 3
12 Chlorhexidine gluconate Phase 3
13 Dermatologic Agents Phase 3
14 Disinfectants Phase 3
15
Ibuprofen Approved Phase 2 15687-27-1 3672
16
Acetaminophen Approved Phase 2 103-90-2 1983
17
Sucralfate Approved Phase 2 54182-58-0
18
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
20
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594
21
Aluminum sulfate Approved Phase 2 10043-01-3
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
23
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
24
Lobeline Investigational Phase 2 90-69-7
25 Anti-Inflammatory Agents Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 2
28 Antipyretics Phase 2
29 Cyclooxygenase Inhibitors Phase 2
30 Antirheumatic Agents Phase 2
31 Gastrointestinal Agents Phase 2
32 Autonomic Agents Phase 2
33 Hormones Phase 2
34 Anti-Ulcer Agents Phase 2
35 Analgesics Phase 2
36 Antacids Phase 2
37 Central Nervous System Depressants Phase 2
38 Tocolytic Agents Phase 2
39 Anti-Arrhythmia Agents Phase 2
40 retinol Phase 2
41 Retinol palmitate Phase 2
42 Anesthetics Phase 2
43 Anticonvulsants Phase 2
44 calcium channel blockers Phase 2
45 Calcium, Dietary Phase 2
46 Neurotransmitter Agents Phase 2
47 Central Nervous System Stimulants Phase 2
48 Nicotinic Agonists Phase 2
49 Cholinergic Agents Phase 2
50 Respiratory System Agents Phase 2
51 Adjuvants, Immunologic Phase 2
52
Suramin Investigational Phase 1 145-63-1 5361
53 Antiparasitic Agents Phase 1
54 Antiprotozoal Agents Phase 1
55 Anthelmintics Phase 1
56
Methylprednisolone hemisuccinate Approved 2921-57-5
57
Methylprednisolone Approved, Vet_approved 83-43-2 6741
58
Prednisolone phosphate Approved, Vet_approved 302-25-0
59 Prednisolone acetate Approved, Vet_approved 52-21-1
60
Prednisolone Approved, Vet_approved 50-24-8 5755
61 Orange Approved
62
Chamomile Approved, Experimental, Investigational
63 Ginger Approved
64
Sodium citrate Approved, Investigational 68-04-2
65 Grape Approved
66
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
67
Lidocaine Approved, Vet_approved 137-58-6 3676
68 Cranberry Approved, Investigational
69
Ethanol Approved 64-17-5 702
70
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
71
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
72
Prednisolone hemisuccinate Experimental 2920-86-7
73 Vitamins
74 Vitamin B Complex
75 Pharmaceutical Solutions
76 Antibiotics, Antitubercular
77 Anti-Bacterial Agents
78 Antiemetics
79 Methylprednisolone Acetate
80 Hypnotics and Sedatives
81 Hormone Antagonists
82 Neuroprotective Agents
83 Natriuretic Agents
84 Protective Agents
85 Antineoplastic Agents, Hormonal
86 glucocorticoids
87 diuretics
88 Skullcap
89 Fluorides
90 Citrate
91 Narcotics
92 Anesthetics, Local
93 Analgesics, Opioid
94 Acidophilus
95 Liver Extracts

Interventional clinical trials:

(showing 85, show less)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
4 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
5 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
6 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
7 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
8 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
9 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
10 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
11 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
12 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
13 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Active, not recruiting NCT02999828 Phase 4
14 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
15 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
16 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
17 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
18 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
19 Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis. Completed NCT02080403 Phase 3 2.5 mg Chlorhexidine gluconate chip
20 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
21 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Active, not recruiting NCT03909074 Phase 3
22 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
23 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
24 A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy Unknown status NCT01247246 Phase 2 SCV-07;Placebo
25 Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling Unknown status NCT00228280 Phase 1, Phase 2
26 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
27 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
28 Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region Completed NCT00230191 Phase 2 RK-0202
29 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant Completed NCT00104065 Phase 2 CG53135-05, velafermin
30 A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant Completed NCT00323518 Phase 2 velafermin;placebo
31 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
32 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
33 Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis Completed NCT01902095 Phase 2
34 Treatment of Smokeless Tobacco Users Completed NCT00218270 Phase 2 Tobacco free snuff
35 Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use Completed NCT00218244 Phase 1, Phase 2
36 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
37 An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) Recruiting NCT04035668 Phase 2 LOU064;Placebo
38 Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Unknown status NCT00000111 Phase 1
39 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
40 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
41 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
42 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
43 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
44 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
45 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
46 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
47 Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study) Terminated NCT02052297 Phase 1
48 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
49 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
50 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
51 Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST) Unknown status NCT00504387
52 Efficacy of Tobacco Cessation for Improving Oral Diseases - Multicenter Prospective Trial Unknown status NCT02737176
53 Long Term Outcomes of EV71 Central Nervous System Infection Unknown status NCT00172393
54 Phase IV, Open-labelled, Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT03281174
55 Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study Completed NCT01769794 Western therapy;JET;Placebo(for JET)
56 An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT02001233
57 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease Completed NCT01554930 Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge);Xiyanping injection plus western therapy
58 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Completed NCT01182532 TCM Syndrome Differentiation and Treatment
59 Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children Completed NCT01255124
60 A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease Completed NCT02066714
61 Does Short Term Discontinuation of Self-performed Oral Hygiene Procedures Influence the Composition of the Salivary Microbiota? Completed NCT02913235
62 Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease Completed NCT02357199
63 Study of the Effect and Safety of Three New Oral Sprays and a Reference Marketed Oral Spray in the Relief of Drug-induced Xerostomia Associated With Hyposialia. Completed NCT02005328
64 Randomized Clinical Trial of a Ginger and Cardamom Gelatin Compared to a Camomile and Lemon Juice Infusion in Control of Xerostomy in Terminally Ill Patients Completed NCT01915966
65 Faringomoss Effectiveness in Inhibiting Acute Throat Pain and Discomfort Completed NCT02894372
66 Pain and Safety of Microneedle Application in the Oral Cavity of Human Volunteers Completed NCT03855397
67 Enhancing Oral Health Care Use by HIV-Positives Completed NCT00444977
68 Polymorphism of the Herpes Simplex Virus Receptor Completed NCT00001648
69 Promoting Oral Health Among Tobacco Quitline Callers Completed NCT02347124
70 Comparation Between Two Surgical Techniques With Acellular Dermal Matrix in Treatment of Gingival Recessions Completed NCT02774967
71 Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders Completed NCT01532323
72 Patient Evaluation and Treatment of Oral Soft Tissue Diseases According to Generally Available, Standard Procedures and Therapeutic Modalities Completed NCT00001601
73 Prospective Studies on Saliva, Microflora, Diet, Oral Status and Quality of Life in Subjects Undergoing Radiation Therapy in the Head and Neck Region Completed NCT02870270
74 Do Traditional or Flavored Tongue Depressors Make for Easier Posterior Completed NCT03095183
75 Analgesic Effects of Peripherally Administered Opioids in a Clinical Model of Chronic Inflammation Completed NCT00001952
76 Assessment of Routine Oral Screening Programs for New Prisoners in France Recruiting NCT03736070
77 Effect of Probiotic Lactobacillus Salivarius and Cranberry on Oral Health of Children Recruiting NCT03919838
78 Pilot Study to Assess PET-MR Imaging for the Detection and Quantitation of Early Fibrosis in Patients With Steatohepatitis and Chemotherapy-associated Steatohepatitis in Hepatic Metastatic Disease Recruiting NCT04063826
79 Development of an Oral Epithelial Dysplasia Informational Needs Questionnaire Recruiting NCT04153266
80 Prevalence of Oral Mucosal Alterations in a Sample of Egyptian Patients With Mucocutaneous Ocular Disorders: A Hospital Based Cross Sectional Study Not yet recruiting NCT03679988
81 A Retrospective Analysis of Oral and Maxillofacial Pathological Lesions in Egyptian Children Not yet recruiting NCT04074395
82 Finger-prick Autologous Blood (FAB) for Use in Dry Mouth Not yet recruiting NCT03530735
83 Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Not yet recruiting NCT03759470
84 Assess and Improve Patient's Self-reported Alcohol Consumption While Attending the Oral Medicine Clinic Terminated NCT02374905
85 Optical Sensor for Photodynamic Detection of Oral Pathology Withdrawn NCT00540774

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR

Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Anatomical Context for Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

19
Mouth

MalaCards organs/tissues related to Mouth Disease:

40
Testes, Kidney, T Cells, Tongue, Skin, B Cells, Salivary Gland

Publications for Mouth Disease

Articles related to Mouth Disease:

(showing 9383, show less)
# Title Authors PMID Year
1
Clinical Outline of Oral Diseases. 42
31735220 2020
2
Mucocutaneous Diseases. 42
31735224 2020
3
Oral Potentially Malignant Disorders. 42
31735231 2020
4
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
5
NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B. 61
31840571 2020
6
Differential antibody responses to the major antigenic sites of FMD virus serotype O after primo-vaccination, multiply-vaccination and after natural exposure. 61
31706082 2020
7
Association of polymorphisms in the vitamin D receptor gene with susceptibility to and severity of hand, foot, and mouth disease caused by coxsackievirus A16. 61
31587312 2020
8
The spatial heterogeneity of the associations between relative humidity and pediatric hand, foot and mouth disease: Evidence from a nation-wide multicity study from mainland China. 61
31874401 2020
9
First isolation of foot and mouth disease virus from wild boars in the Middle East. 61
32034998 2020
10
Foot-and-mouth disease outbreaks in captive scimitar-horned oryx (Oryx dammah). 61
32011088 2020
11
Inactivation of foot-and-mouth disease virus A/IRN/8/2015 with commercially available lysis buffers. 61
32035122 2020
12
The first full genome characterization of an Iranian Foot and mouth disease virus. 61
32023478 2020
13
The impact of changing farm structure on foot-and-mouth disease spread and control: A simulation study. 61
32012445 2020
14
Enhanced Efficacy of Immunization with a Foot-and-Mouth Disease Multi-Epitope Subunit Vaccine Using Mannan-Decorated Inulin Microparticles. 61
32002844 2020
15
Cell culture propagation of foot-and-mouth disease virus: adaptive amino acid substitutions in structural proteins and their functional implications. 61
31776851 2020
16
Effects of regional differences and demography in modelling foot-and-mouth disease in cattle at the national scale. 61
31897292 2020
17
Engineering viable foot-and-mouth disease viruses with increased acid stability facilitate the development of improved vaccines. 61
31900553 2020
18
Data on prevalence, distribution and risk factors for Foot and Mouth Disease in grazing cattle in haor areas of Bangladesh. 61
31956666 2020
19
Inactivation of foot-and-mouth disease virus in epithelium samples for safe transport and processing in low-containment laboratories. 61
31705919 2020
20
The interference effect of maternally-derived antibodies on the serological performance of pigs immunized with a foot-and-mouth disease oil emulsion vaccine. 61
31892447 2020
21
Substitution 3A protein of foot-and-mouth disease virus of attenuated ZB strain rescued the viral replication and infection in bovine cells. 61
31791012 2020
22
Negatively charged amino acids at the foot-and-mouth disease virus capsid reduce the virion-destabilizing effect of viral RNA at acidic pH. 61
32015411 2020
23
Immunogenicity of imported foot-and-mouth vaccines in different species in Mongolia. 61
31926753 2020
24
Crystallization of SLA-2*04:02:02 complexed with a CTL epitope derived from FMDV. 61
31760318 2020
25
Estimating viral bottleneck sizes for FMDV transmission within and between hosts and implications for the rate of viral evolution. 61
31897294 2020
26
FMD vaccine matching: Inter laboratory study for improved understanding of r1 values. 61
31765721 2020
27
Genetic characterization of VP1 of coxsackieviruses A2, A4, and A10 associated with hand, foot, and mouth disease in Vietnam in 2012-2017: endemic circulation and emergence of new HFMD-causing lineages. 61
32008121 2020
28
Non-polio enteroviruses among healthy children in the Philippines. 61
32013921 2020
29
Reversible Cerebral Angiopathy after Viral Infection in a Pediatric Patient with Genetic Variant of RNF213. 61
31818681 2020
30
Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. 61
31892446 2020
31
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease. 61
31961293 2020
32
Hand-foot-and-mouth disease in uruguay: Coxsackievirus A6 identified as causative of an outbreak in a rural childcare center. 61
31502682 2020
33
Protective Immunity Elicited by VP1 Chimeric Antigens of Bacterial Ghosts against Hand-Foot-and-Mouth Disease Virus. 61
32024212 2020
34
First detection of foot-and-mouth disease virus O/ME-SA/ Ind2001e sublineage in Jordan. 61
31549490 2020
35
High-Resolution Composition Analysis of an Inactivated Polyvalent Foot-and-Mouth Disease Vaccine. 61
31963122 2020
36
Utilizing milk from pooling facilities as a novel approach for foot-and-mouth disease surveillance. 61
31961008 2020
37
Development and evaluation of silver amplification immunochromatography kit for foot-and-mouth disease virus antigen detection. 61
31669454 2020
38
Genetic Determinants of Altered Virulence of Type O Foot-and-Mouth Disease Virus. 61
31915277 2020
39
Timeliness of vesicular disease notification system in Brazilian foot-and-mouth disease surveillance programme. 61
31965759 2020
40
FOOT-AND-MOUTH DISEASE IN EXPERIMENTALLY INFECTED MULE DEER (ODOCOILEUS HEMIONUS). 61
31329525 2020
41
Evaluating the utility of national-scale data to estimate the local risk of foot-and-mouth disease in endemic regions. 61
31408585 2020
42
Model of persistent foot-and-mouth disease virus infection in multilayered cells derived from bovine dorsal soft palate. 61
31419374 2020
43
Horizontal transmission of foot-and-mouth disease virus O/JPN/2010 among different animal species by direct contact. 61
31482692 2020
44
Comparison of chemical extraction methods for determination of 146S content in foot-and-mouth disease oil-adjuvanted vaccine. 61
31562676 2020
45
Ribosomal Protein L13 Promotes IRES-Driven Translation of Foot-and-Mouth Disease Virus in a Helicase DDX3-Dependent Manner. 61
31619563 2020
46
A Single Dose of Dendrimer B2T Peptide Vaccine Partially Protects Pigs against Foot-and-Mouth Disease Virus Infection. 61
31936706 2020
47
Characterization of SAT2 foot-and-mouth disease 2013/2014 outbreak viruses at the wildlife-livestock interface in South Africa. 61
31984622 2020
48
A bivalent B-cell epitope dendrimer peptide can confer long lasting immunity in swine against foot-and-mouth disease. 61
31994334 2020
49
Foot-and-Mouth Disease Virus Serotype O/CATHAY Genome Sequences from Five Outbreaks in Vietnam, 2017 to 2019. 61
32001559 2020
50
Immunogenicity and protective efficacy of 3A truncated negative marker foot-and-mouth disease virus serotype A vaccine. 61
32002597 2020
51
Improved foot-and-mouth disease vaccine with O PanAsia-2 strain protect pigs against O/Jincheon/SKR/2014 originated from South Korea. 61
31810782 2020
52
Corrigendum to "Generation of acid resistant virus like particles of vaccine strains of foot-and-mouth disease virus (FMDV)" [Biologicals 60 (2019) 28-35]. 61
31767491 2020
53
Foot-and-mouth disease virus 3A protein causes upregulating of autophagy-related protein LRRC25 to inhibit the G3BP1-mediated RLH signaling pathway. 61
31996428 2020
54
Pervasive within-host recombination and epistasis as major determinants of the molecular evolution of the foot-and-mouth disease virus capsid. 61
31905219 2020
55
Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage. 61
31947514 2020
56
Multiplexed DIVA tests for rapid detection of FMDV infection/circulation in endemic countries. 61
31832714 2020
57
Development and evaluation of swine vesicular disease isotype-specific antibody ELISAs based on recombinant virus-like particles. 61
31538404 2020
58
A nonstructural 2B protein of enterovirus A71 increases cytosolic Ca2+ and induces apoptosis in human neuroblastoma SH-SY5Y cells. 61
31933192 2020
59
The antibody response induced FMDV vaccines in sheep correlates with early transcriptomic responses in blood. 61
31908850 2020
60
Epitope Containing Short Peptides Capture Distinct IgG Serodynamics that Enable DIVA for Live-attenuated Vaccines. 61
31896600 2020
61
Development of an enterovirus 71 vaccine efficacy test using human scavenger receptor B2 transgenic mice. 61
31896594 2020
62
Network analysis of swine movements in a multi-site pig production system in Iowa, USA. 61
31786406 2020
63
HSV-1 Amplicon Vectors as Genetic Vaccines. 61
31617175 2020
64
Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine. 61
31982260 2020
65
Coxsackievirus A6 infection presenting with different clinical phenotypes of hand-foot-and-mouth disease in two brothers at the same time. 61
31957699 2020
66
Clinical and epidemiological characteristics of Coxsackievirus A6- and Enterovirus 71-associated clinical stage 2 and 3 severe hand, foot, and mouth disease in Guangxi, Southern China, 2017. 61
31629866 2020
67
Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease. 61
31939669 2020
68
Newly emerged enterovirus-A71 C4 sublineage may be more virulent than B5 in the 2015-2016 hand-foot-and-mouth disease outbreak in northern Vietnam. 61
31932599 2020
69
Hand, foot, and mouth disease in Changsha City, China, 2009-2017: a new method to analyse the epidemiological characteristics of the disease. 61
31596157 2020
70
Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. 61
32004757 2020
71
One-Step Monitoring of Multiple Enterovirus 71 Infection-Related MicroRNAs Using Core-Satellite Structure of Magnetic Nanobeads and Multicolor Quantum Dots. 61
31762266 2020
72
Acute enterovirus infections significantly alter host cellular DNA methylation status. 61
31927072 2020
73
A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. 61
31944333 2020
74
Exosomes from EV71-infected oral epithelial cells can transfer miR-30a to promote EV71 infection. 61
31958204 2020
75
Establishment of Asia-Pacific Network for Enterovirus Surveillance. 61
31679864 2020
76
Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. 61
32027857 2020
77
Multi-modal Diagnosis of Infectious Diseases in the Developing World. 61
31944967 2020
78
Next generation sequencing of human enterovirus strains from an outbreak of enterovirus A71 shows applicability to outbreak investigations. 61
31790967 2020
79
Downregulation of miR-155-5p facilitates enterovirus 71 replication through suppression of type I IFN response by targeting FOXO3/IRF7 pathway. 61
31856677 2020
80
Impact of Ambient Temperature and Relative Humidity on the Incidence of Hand-Foot-Mouth Disease in Wuhan, China. 61
31936369 2020
81
Salvianolic Acid B Inhibits Hand-Foot-Mouth Disease Enterovirus 71 Replication through Enhancement of AKT Signaling Pathway. 61
31752055 2020
82
Estimation of the reproduction number and identification of periodicity for HFMD infections in northwest China. 61
31568791 2020
83
Cellular receptors for enterovirus A71. 61
31924205 2020
84
Importance of livestock diseases identified using participatory epidemiology in the highlands of Ethiopia. 61
31898026 2020
85
The Management of Cow Shelters (Gaushalas) in India, Including the Attitudes of Shelter Managers to Cow Welfare. 61
32012807 2020
86
Jumonji domain-containing protein 6 protein and its role in cancer. 61
31961032 2020
87
Prioritization of livestock transboundary diseases in Belgium using a multicriteria decision analysis tool based on drivers of emergence. 61
31520577 2020
88
Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung. 61
31897589 2020
89
Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle. 61
31718901 2020
90
Production of foot-and-mouth disease virus SAT2 VP1 protein. 61
31912326 2020
91
The epidemiological characteristics and spatio-temporal analysis of childhood hand, foot and mouth disease in Korea, 2011-2017. 61
31931518 2020
92
Spatial heterogeneity of the association between temperature and hand, foot, and mouth disease risk in metropolitan and other areas. 61
31954246 2020
93
Hand, foot and mouth disease caused by Coxsackie viruses A6 and A16 in Assam, Northeast India: A need for surveillance. 61
30860171 2020
94
Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. 61
31911601 2020
95
Pathogenic characteristics of hand, foot and mouth disease in Shaanxi Province, China, 2010-2016. 61
31969644 2020
96
Oral Health Implications of Bariatric Surgery in Morbidly Obese Patients: An Integrative Review. 61
31940140 2020
97
Foot-and-Mouth Disease Virus Capsid Protein VP1 Interacts with Host Ribosomal Protein SA To Maintain Activation of the MAPK Signal Pathway and Promote Virus Replication. 61
31694957 2020
98
Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by Coxsackievirus A6. 61
31683008 2020
99
Atypical hand-foot-and-mouth disease. 61
31959658 2020
100
Characterization of transboundary foot-and-mouth disease viruses in Nigeria and Cameroon during 2016. 61
31880066 2019
101
In vitro antiviral efficacy of pleconaril and ribavirin on foot-and-mouth disease virus replication. 61
31890754 2019
102
Genome Sequences of Four Foot-and-Mouth Disease Virus SAT 1 Topotype X Isolates from Cameroon. 61
31806747 2019
103
Seroprevalence and molecular characterization of foot-and-mouth disease virus in Chad. 61
31845545 2019
104
Development of Monoclonal Antibody Specific to Foot-and-Mouth Disease Virus Type A for Serodiagnosis. 61
31861046 2019
105
[Levels of lymphocyte subsets, immunoglobulins, and complement C3 and C4 in children with hand-foot-mouth disease]. 61
31874660 2019
106
Biomineralization improves the thermostability of foot-and-mouth disease virus-like particles and the protective immune response induced. 61
31599276 2019
107
The DEAD-Box RNA Helicase DDX1 Interacts with the Viral Protein 3D and Inhibits Foot-and-Mouth Disease Virus Replication. 61
31359346 2019
108
Silencing of the foot-and-mouth disease virus internal ribosomal entry site by targeting relatively conserved region among serotypes. 61
31367998 2019
109
Three-percent sucrose acts as a thermostabilizer for cell-adapted foot-and-mouth disease virus without any negative effect on viral growth. 61
31883170 2019
110
Evaluation of novel inactivated vaccines for the SAT 1, SAT 2 and SAT 3 serotypes of foot-and-mouth disease in pigs. 61
31842907 2019
111
A review and meta-analysis of the epidemiology and clinical presentation of coxsackievirus A6 causing hand-foot-mouth disease in China and global implications. 61
31811676 2019
112
Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate. 61
31347713 2019
113
Implication of Broadly Neutralizing Bovine Monoclonal Antibodies in the Development of an Enzyme-Linked Immunosorbent Assay for Detecting Neutralizing Antibodies against Foot-and-Mouth Disease Virus Serotype O. 61
31578261 2019
114
Risk factors of foot and mouth disease in an endemic area on low vaccination rate in Xayaboury province of Lao People's Democratic Republic (Lao PDR). 61
31729631 2019
115
Modeling the role of carrier and mobile herds on foot-and-mouth disease virus endemicity in the Far North Region of Cameroon. 61
31353297 2019
116
Incorporating Contact Network Uncertainty in Individual Level Models of Infectious Disease using Approximate Bayesian Computation. 61
31812945 2019
117
Hederacolchiside C inhibits Enterovirus 71 propagation through activating innate immunity. 61
31401030 2019
118
Plant-Produced Anti-Enterovirus 71 (EV71) Monoclonal Antibody Efficiently Protects Mice Against EV71 Infection. 61
31805650 2019
119
DDX56 cooperates with FMDV 3A to enhance FMDV replication by inhibiting the phosphorylation of IRF3. 61
31445188 2019
120
Understanding the vulnerability of beef producers in Australia to an FMD outbreak using a Bayesian Network predictive model. 61
31981953 2019
121
Interplays between Enterovirus A71 and the innate immune system. 61
31787104 2019
122
Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10. 61
31851566 2019
123
Multiple divergent Human mastadenovirus C co-circulating in mainland of China. 61